Editas Medicine, Inc. (EDIT) has a consensus analyst rating of Buy, based on 25 analysts covering the stock. Of those, 14 recommend buying, 9 recommend holding, and 2 recommend selling.
The analyst consensus price target for EDIT is $6.00, representing a +77.0% upside from the current price of $3.39. Price targets range from a low of $6.00 to a high of $6.00.
